Get the Stockscreener App
0.00
100.00%
-8.61
After Hours:
8.61
8.61
+
Y Mabs Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
See More
Previous Close:
$8.61
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$391.22M
Revenue:
$84.82M
Net Income/Loss:
$-21.43M
P/E Ratio:
0.00
EPS:
-0.49
Net Cash Flow:
$-27.23M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$8.61
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Name
Y Mabs Therapeutics Inc
Sector
Industry
Phone
646-885-8505
Address
202 CARNEGIE CENTER, PRINCETON, NY
Compare YMAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
0.00 | 391.22M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-18-24 | Initiated | Oppenheimer | Outperform |
| Aug-16-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-28-24 | Initiated | Truist | Buy |
| May-10-23 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-27-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-23 | Downgrade | Cowen | Outperform → Market Perform |
| Dec-02-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-31-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-31-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-03-22 | Resumed | Guggenheim | Buy |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-16-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-07-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-23-21 | Resumed | Cowen | Outperform |
| Mar-22-21 | Resumed | JP Morgan | Overweight |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Overweight |
| May-01-20 | Initiated | Janney | Buy |
| Apr-29-20 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Initiated | Wedbush | Outperform |
| Apr-01-19 | Initiated | H.C. Wainwright | Buy |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Oct-16-18 | Initiated | BofA/Merrill | Buy |
View All
Y Mabs Therapeutics Inc Stock (YMAB) Latest News
Earnings Miss: Can Y mAbs Therapeutics Inc continue delivering strong returnsJuly 2025 Momentum & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Entry Recap: What is the fair value of Y mAbs Therapeutics Inc stock now - Bộ Nội Vụ
Market Review: Is Y mAbs Therapeutics Inc showing insider buyingPrice Action & Scalable Portfolio Growth Ideas - baoquankhu1.vn
YMAB stock touches 52-week low at $6 amid challenging year - MSN
Y-mAbs Therapeutics, Inc.Common Stock (NQ: YMAB - FinancialContent
MSN Money - MSN
(YMAB) Risk Channels and Responsive Allocation - Stock Traders Daily
Is Y mAbs Therapeutics Inc a good long term investmentPrice Momentum Alerts & The Future of Wealth Is Just a Click Away - earlytimes.in
Trading the Move, Not the Narrative: (YMAB) Edition - Stock Traders Daily
Will Y mAbs Therapeutics Inc. stock outperform international peersJuly 2025 Snapshot & AI Powered Market Entry Ideas - Улправда
Why Y mAbs Therapeutics Inc. stock is a must watch in 20252025 Geopolitical Influence & AI Forecasted Stock Moves - Улправда
Will Y mAbs Therapeutics Inc. stock outperform tech sector in 2025July 2025 Analyst Calls & Growth Focused Stock Pick Reports - Улправда
How Y mAbs Therapeutics Inc. stock benefits from strong dollarJuly 2025 Recap & Weekly Momentum Picks - Улправда
How Y mAbs Therapeutics Inc. stock compares to industry benchmarksTechnology Stock Trends & Access Free Tools and Start Investing - ulpravda.ru
The Technical Signals Behind (YMAB) That Institutions Follow - Stock Traders Daily
Is Y mAbs Therapeutics Inc. stock attractive for ETFsPortfolio Profit Report & Precise Trade Entry Recommendations - newser.com
Is Y mAbs Therapeutics Inc. stock trading at a premium valuationGap Down & Weekly Watchlist for Hot Stocks - newser.com
United States Brain Cancer Treatment Market in 2025 | Novel Drug - openPR.com
Why Y mAbs Therapeutics Inc. stock is considered a top pickEarnings Recap Summary & Fast Entry Momentum Trade Alerts - newser.com
Can Y mAbs Therapeutics Inc. stock withstand economic slowdownQuarterly Growth Report & Technical Buy Zone Confirmations - newser.com
Can Y mAbs Therapeutics Inc. stock continue upward trendDividend Hike & AI Optimized Trading Strategy Guides - newser.com
What’s next for Y mAbs Therapeutics Inc. stock priceQuarterly Performance Summary & Verified Chart Pattern Trade Signals - newser.com
How strong is Y mAbs Therapeutics Inc. stock balance sheet2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
Is it too late to sell Y mAbs Therapeutics Inc.Market Activity Summary & Consistent Income Trade Recommendations - newser.com
Dr. Vignesh Rajah Appointed as SERB Pharmaceuticals’ Chief Medical Officer - GlobeNewswire
Is Y mAbs Therapeutics Inc. stock a dividend growth opportunityWeekly Profit Summary & Verified Entry Point Detection - newser.com
Does Y mAbs Therapeutics Inc. stock trade at a discount to peersM&A Rumor & Safe Entry Zone Identification - newser.com
Institutional scanner results for Y mAbs Therapeutics Inc.July 2025 Trends & Stepwise Trade Signal Implementation - newser.com
How Y mAbs Therapeutics Inc. stock trades before earningsMarket Performance Summary & Fast Exit and Entry Strategy Plans - newser.com
Is Y mAbs Therapeutics Inc. stock a buy on dipsWeekly Gains Report & Verified Entry Point Detection - Fundação Cultural do Pará
Why analysts upgrade Y mAbs Therapeutics Inc. stockGap Up & Safe Entry Trade Signal Reports - newser.com
How geopolitical tensions affect Y mAbs Therapeutics Inc. stockJuly 2025 Patterns & Reliable Momentum Entry Alerts - newser.com
Precision Trading with Y-mabs Therapeutics Inc. (YMAB) Risk Zones - news.stocktradersdaily.com
Is Y mAbs Therapeutics Inc. stock reversal real or fake2025 Momentum Check & Safe Investment Capital Preservation Plans - newser.com
Y Mabs Therapeutics Inc Stock (YMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):